Monarch Medical Technologies Granted U.S. Patent for Approach to Inpatient Insulin Therapy
Summary
“This new patent covers aspects of our EndoTool® Glucose Management System, a Class II FDA-cleared software suite, providing patient-specific insulin dosing recommendations,” said Linda Beneze, President and CEO of Monarch Medical Technologies.We recognize the need to secure our intellectual property, which provides unique advantages that are best demonstrated in the improved clinical outcomes and associated cost reductions that our clients have experienced.”With EndoTool, Monarch has been a leading innovator in developing an electronic glucose management system for safer insulin dosing in the inpatient setting.Studies have shown that proper glucose management during inpatient treatment reduces morbidity, mortality, and cost of care.As a Class II FDA-cleared, patented software suite, EndoTool has enabled more than 235 hospitals to provide unsurpassed patient-specific glycemic control across a broad population of patients, and ultimately deliver better, safer care.